Skip to main
TVTX
TVTX logo

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 46%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics has demonstrated strong commercial execution despite previous REMS requirements, signaling robust demand for their product, FILSPARI. The removal and reduction of these REMS requirements are expected to enhance prescriber adoption, supporting a more streamlined treatment process for both patients and healthcare providers. Additionally, the favorable stock reaction following these developments indicates positive market sentiment towards the company's positioning in the competitive landscape of rare kidney disorder treatments.

Bears say

The outlook for Travere Therapeutics’s stock remains negative primarily due to the potential for failed or inconclusive clinical trials, which could hinder the advancement of its key pipeline candidate, sparsentan. Additionally, the company faces challenges in securing sufficient funding necessary to progress its drugs through the development pathway, further exacerbating financial uncertainties. Investor sentiment is negatively impacted by mixed regulatory decisions, heightened scrutiny from the FDA, and a general atmosphere of trepidation across the biotech sector, which collectively diminish confidence in the company's prospects.

Travere Therapeutics (TVTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 46% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 13 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.